Gilgamesh Pharma key facts
as of Oct 2026- Developer of novel chemical entities designed to transform the treatment of psychiatric disorders through rapid-acting and durable therapies.
- Gilgamesh Pharma is valued at approximately $188.5M as of Oct 2026 (last reported valuation).
- It has raised $135.8M across 3 recorded rounds; the latest was Seed Round ($2.3M) in Mar 2026.
- Notable investors include Y Combinator, Alumni Ventures, Pioneer Fund, Offline Ventures, What If Ventures — 24 tracked in total.
- 1 investment vehicle was formed to buy Gilgamesh Pharma shares in the last 12 months, reporting $1.8M sold to 25 investors, per SEC Form D filings.
- Gilgamesh Pharma has filed 2 Form Ds with the SEC, most recently Mar 2026 ($2.3M sold to 3 investors).
- Status: Privately Held (backing).
Gilgamesh Pharma's last reported valuation, May 2022. Nothing priced has surfaced since.
- ·The complete investor list: 24 names
- ·Watch Gilgamesh Pharma: the Monday email on marks, rounds and moves
Gilgamesh Pharma funding rounds
3 roundsVehicles formed to buy Gilgamesh Pharma shares
secondary demand · SEC Form D filingsIn the last 12 months, 1 investment vehicle were formed to buy Gilgamesh Pharma shares, reporting $1.8M sold to 25 investors. Most recent filing Mar 2026.
Membership and data by Private Market View
Who backs Gilgamesh Pharma
24+Membership and data by Private Market View
Gilgamesh Pharma valuation
Gilgamesh Pharma's last reported valuation was $189 million in May 2022. No priced round, secondary trade or fund mark has surfaced since.
How much has Gilgamesh Pharma raised?
Gilgamesh Pharma has raised $136 million across 3 recorded rounds since 2026. The largest was a $6.1 million early-stage round in Jan 2026; the most recent was a $2.3 million seed round in Mar 2026.
Gilgamesh Pharma has filed 2 Form Ds with the SEC, most recently in Mar 2026 ($2.3 million sold to 3 investors).
Institutional holders and vehicles
In the last 12 months, 1 investment vehicle was formed to buy Gilgamesh Pharma shares, reporting $1.8 million sold to 25 investors, per SEC Form D filings (most recent Mar 2026).
Gilgamesh Pharma investors
24 investors are on record for Gilgamesh Pharma, including Y Combinator, Alumni Ventures, Pioneer Fund and Offline Ventures. By type, the record holds 6 venture capital firms, 1 private equity firm and 1 fund of funds. The seed round in Mar 2026 drew 3 investors.
About Gilgamesh Pharma
Developer of novel chemical entities designed to transform the treatment of psychiatric disorders through rapid-acting and durable therapies. The company offers AI-powered drug discovery capabilities, advanced medicinal chemistry expertise, and orally bioavailable neuroactive compounds with improved safety profiles, enabling patients with depression, anxiety, and substance use disorders to achieve faster relief and sustained therapeutic effects.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2019
- Employees
- 15
- Website
- gilgameshpharmaceutical.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.